Karbis

Leaflet attached to the packaging: patient information

Warning! The leaflet should be kept. Information on the immediate packaging in a foreign language.

Karbis (Canocord)

32 mg, tablets
Candesartan cilexetil
Karbis and Canocord are different trade names for the same drug.

The patient should carefully read the contents of the leaflet before taking the drug, as it contains important information for the patient.

• The patient should keep this leaflet so that they can read it again if necessary.
• In case of any doubts, the patient should consult a doctor or pharmacist.
• This drug has been prescribed to a specific person. It should not be given to others. The drug may harm another person, even if the symptoms of their illness are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Karbis and what is it used for
• 2. Important information before taking Karbis
• 3. How to take Karbis
• 4. Possible side effects
• 5. How to store Karbis
• 6. Package contents and other information

1. What is Karbis and what is it used for

The drug is called Karbis. The active substance of the drug is candesartan cilexetil. It belongs to a group of drugs called angiotensin II receptor antagonists. It causes relaxation and dilation of blood vessels. This helps to lower blood pressure. Karbis also makes it easier for the heart to pump blood to all parts of the body.
Karbis is used:

• to treat high blood pressure (hypertension) in adults and in children and adolescents from 6 to 18 years old,
• in adult patients to treat heart failure with reduced cardiac function, when angiotensin-converting enzyme inhibitors (ACE) (Angiotensin Converting Enzyme Inhibitors, ACEI) cannot be used or as a supplement to ACE inhibitor therapy, when symptoms of heart failure persist despite treatment, and mineralocorticoid receptor antagonists (MRA) cannot be used. (ACE inhibitors and MRAs are drugs used to treat heart failure).

2. Important information before taking Karbis

When not to take Karbis:

• if the patient is allergic to candesartan cilexetil or any of the other ingredients of this drug (listed in section 6),
• during pregnancy over 3 months (Karbis should also be avoided in early pregnancy - see section "Pregnancy and breastfeeding"),
• in case of severe liver disease or bile duct obstruction (obstruction of bile flow from the gallbladder),
• in children under 1 year of age,
• if the patient has diabetes or kidney problems and is being treated with a blood pressure-lowering drug containing aliskiren.

In case of doubts whether any of the above situations apply to the patient, they should consult a doctor or pharmacist before taking Karbis.

Warnings and precautions

Before starting to take Karbis, the patient should discuss it with their doctor or pharmacist:

• if there are heart, liver, or kidney problems or if the patient is undergoing dialysis,
• if the patient has recently undergone a kidney transplant,
• if the patient has had severe vomiting or diarrhea,
• if the patient has a disease of the adrenal glands called Conn's syndrome (primary hyperaldosteronism),
• if the patient has low blood pressure,
• if the patient has ever had a stroke,
• the patient must inform their doctor about pregnancy, suspected pregnancy, or planned pregnancy. Karbis is not recommended during early pregnancy. Karbis should not be taken after 3 months of pregnancy, as it may seriously harm the fetus (see section "Pregnancy and breastfeeding").
• if the patient is taking any of the following drugs for high blood pressure:
• an ACE inhibitor (e.g., enalapril, lisinopril, ramipril), especially if the patient has kidney problems related to diabetes,
• aliskiren.
• if the patient is taking an ACE inhibitor and a drug belonging to a group of drugs known as mineralocorticoid receptor antagonists (MRA) at the same time. These drugs are used to treat heart failure (see "Karbis and other drugs").

The doctor may monitor kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood at regular intervals.
See also the information under the heading "When not to take Karbis:".
The doctor may recommend more frequent checks and tests if any of the above points apply to the patient.
If the patient is going to have surgery, they should inform their doctor or dentist that they are taking Karbis. This is because Karbis, in combination with some anesthetics, may cause a decrease in blood pressure.

Children and adolescents

The use of Karbis has been studied in children. For further information, the patient should talk to their doctor. Karbis should not be given to children under 1 year of age due to the potential risk to kidney development.

Karbis and other drugs

The patient should tell their doctor or pharmacist about all the drugs they are taking, have recently taken, or plan to take.
Karbis may affect the action of other drugs, and other drugs may affect Karbis.
If the patient is taking certain drugs, the doctor may periodically recommend blood tests.
In particular, the patient should inform their doctor if they are taking the following drugs:

• other blood pressure-lowering drugs, including beta-blockers, diazoxide, and ACE inhibitors, such as enalapril, captopril, lisinopril, or ramipril,
• non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, diclofenac, celecoxib, or etoricoxib (drugs that relieve pain and inflammation),
• acetylsalicylic acid (in a dose greater than 3 g per day) (a drug that relieves pain and inflammation),
• potassium supplements, salt substitutes containing potassium (drugs that increase potassium levels in the blood),
• heparin (a blood-thinning drug),
• diuretics,
• lithium (a drug used to treat mental disorders).

The doctor may need to change the dose and/or take other precautions:

• if the patient is taking an ACE inhibitor or aliskiren (see also the information under the heading "When not to take Karbis:" and "Warnings and precautions"),
• if the patient is taking an ACE inhibitor and a drug used to treat heart failure, known as a mineralocorticoid receptor antagonist (MRA), at the same time (e.g., spironolactone, eplerenone).

Karbis with food, drink, and alcohol

Karbis can be taken with or without food.
The patient should consult their doctor if they plan to consume alcohol while taking Karbis. Karbis may cause dizziness or fainting.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this drug.
Pregnancy
The patient should inform their doctor about suspected or planned pregnancy. The doctor will usually recommend stopping Karbis before planned pregnancy or as soon as pregnancy is confirmed and recommend taking a different drug instead of Karbis. Karbis is not recommended during early pregnancy and should not be taken after 3 months of pregnancy, as it may seriously harm the fetus (see section "Pregnancy and breastfeeding").
Breastfeeding
The patient should inform their doctor about breastfeeding or intending to breastfeed. Karbis is not recommended during breastfeeding, especially in the case of breastfeeding a newborn or premature baby. The doctor may recommend a different drug.

Driving and using machines

While taking Karbis, some patients may feel tired and dizzy. If such symptoms occur, the patient should not drive, use tools, or operate machines.

Karbis contains lactose monohydrate, a type of sugar

If the patient has been informed by their doctor that they have an intolerance to some sugars, they should contact their doctor before taking this drug.

3. How to take Karbis

This drug should always be taken as directed by the doctor or pharmacist. In case of doubts, the patient should consult their doctor or pharmacist. It is important to take Karbis every day.
Karbis is available in doses of 8 mg, 16 mg, and 32 mg.
Karbis can be taken with or without food. The tablet should be swallowed with water. The tablets should be taken every day at about the same time. This will help the patient remember to take their dose. The tablet can be divided into equal doses.

High blood pressure

The recommended dose of candesartan is 8 mg once a day. The doctor may increase the dose to 16 mg once a day and then to 32 mg once a day, depending on the patient's response to treatment.
The doctor may recommend a lower initial dose for certain patients, e.g., patients with liver or kidney problems, patients who have lost a lot of fluid, e.g., due to vomiting, diarrhea, or the use of diuretics.
In some black patients, the response to treatment may be weaker if Karbis is used as monotherapy. In this case, higher doses may be necessary.

Use in children and adolescents with high blood pressure

Children from 6 to 18 years old:
The recommended initial dose is 4 mg once a day.
Patients with a body weight of less than 50 kg: in some patients with insufficient blood pressure control, the doctor may decide to increase the dose of Karbis to a maximum of 8 mg once a day.
Patients with a body weight of 50 kg or more: in some patients with insufficient blood pressure control, the doctor may decide to increase the dose of Karbis to 8 mg once a day and then to 16 mg once a day.

Heart failure in adults

The recommended initial dose of candesartan is 4 mg once a day. The doctor may increase the dose by doubling it, at intervals of at least 2 weeks, to 32 mg once a day. Karbis can be taken with other drugs used to treat heart failure, and the doctor will decide which therapy is most suitable for the patient.

Taking a higher dose of Karbis than recommended

In case of taking a higher dose of Karbis than recommended, the patient should immediately contact their doctor or pharmacist.

Missing a dose of Karbis

The patient should not take a double dose to make up for a missed dose. The next dose should be taken at the usual time.

Stopping Karbis treatment

Stopping treatment may lead to a recurrence of high blood pressure. The patient should not stop taking Karbis unless their doctor recommends it.
In case of any further doubts about taking this drug, the patient should consult their doctor or pharmacist.

4. Possible side effects

Like all drugs, Karbis can cause side effects, although not everybody gets them.
It is important for the patient to know about the possibility of their occurrence.

The patient should stop taking Karbis and seek medical help immediately if they experience any of the following allergic reactions:

• difficulty breathing, with swelling of the face, lips, tongue, and/or throat, with or without swelling,
• swelling of the face, lips, tongue, and/or throat, which may cause difficulty swallowing,
• severe itching of the skin (with raised hives).

Karbis may cause a decrease in the number of white blood cells. This may lead to a decreased resistance to infections, and the patient may experience fatigue, infection, or fever. If such symptoms occur, the patient should contact their doctor. The doctor may periodically recommend blood tests to check if Karbis is causing any blood disorders (agranulocytosis).
Other possible side effects include:

Common side effects (may affect up to 1 in 10 people):

• Dizziness/spinning sensation
• Headache
• Respiratory tract infection
• Low blood pressure. This may cause dizziness or fainting.
• Changes in blood test results:
• increased potassium levels in the blood, especially if the patient has kidney problems or heart failure. In case of significant increase, fatigue, weakness, irregular heartbeat, or tingling may occur.
• effect on kidney function, especially in patients with existing kidney problems or heart failure. In very rare cases, kidney failure may occur.

Very rare side effects (may affect up to 1 in 10,000 people):

• Swelling of the face, lips, tongue, and/or throat
• Decrease in the number of red or white blood cells. Fatigue, infection, or fever may occur.
• Skin rash, hives
• Itching
• Back pain, joint and muscle pain
• Changes in liver function, including hepatitis. Fatigue, yellowing of the skin and eyes, and flu-like symptoms may occur.
• Cough
• Nausea
• Changes in blood test results:
• decrease in sodium levels in the blood. In case of significant decrease, weakness, lack of energy, or muscle cramps may occur.

Frequency not known (frequency cannot be estimated from the available data):

• Diarrhea.

Side effects in children treated for high blood pressure seem to be similar to those observed in adult patients but occur more frequently. Very common side effects in children include pharyngitis, and common side effects include rhinopharyngitis, fever, and tachycardia, although these side effects were not observed in adults.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be gathered on the safety of the drug.

5. How to store Karbis

The drug should be stored out of sight and reach of children.
The drug should not be used after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
There are no special precautions for storage.
Drugs should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of drugs that are no longer needed. This will help protect the environment.

6. Package contents and other information

What Karbis contains

• The active substance of the drug is candesartan cilexetil. Each tablet contains 32 mg of candesartan cilexetil.
• The other ingredients are: lactose monohydrate, cornstarch, macrogol 8000, hydroxypropylcellulose, calcium carmellose, magnesium stearate, and red iron oxide (E172).

What Karbis looks like and what the package contains

The 32 mg tablets are pink, round, slightly convex with beveled edges and a score line on one side, with a diameter of 9 mm.
The tablet can be divided into equal doses.
Packaging: 14, 28, 30, 56, or 60 tablets in blisters, in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in the Czech Republic, the country of export:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Str. 5, 27472 Cuxhaven, Germany

Parallel importer:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Marketing authorization number in the Czech Republic, the country of export: 58/567/11-C

Parallel import authorization number: 364/18

Date of leaflet approval:27.11.2023
[Information about the trademark]